Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06835140
CD123-CD16-NK Cells Immunotherapy for AML (CD123-CD16-NK)
CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)
Sponsor: Chinese PLA General Hospital
Updated 1 time since 2025 Last updated: Feb 23, 2025 Started: Feb 21, 2025 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates AML (Acute Myelogenous Leukemia) and CD123+ Acute Myeloid Leukemia and is currently actively recruiting participants. Chinese PLA General Hospital leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Chinese PLA General Hospital
- Chunji Gao
Data source: Chinese PLA General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .